New drug targets stubborn cancers in early trial
Disease control
Not yet recruiting
This study tests an experimental drug called LCB02A in people with advanced solid tumors that have a specific marker (CLDN18.2) and have stopped responding to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, f…
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated May 07, 2026 18:43 UTC